Medicenna Therapeutics Corp. (MDNA): Price and Financial Metrics


Medicenna Therapeutics Corp. (MDNA): $1.01

0.06 (+5.99%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add MDNA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

MDNA Stock Price Chart Interactive Chart >

Price chart for MDNA

MDNA Price/Volume Stats

Current price $1.01 52-week high $4.02
Prev. close $0.95 52-week low $0.91
Day low $0.93 Volume 26,300
Day high $1.01 Avg. volume 103,620
50-day MA $1.16 Dividend yield N/A
200-day MA $1.78 Market Cap 56.56M

Medicenna Therapeutics Corp. (MDNA) Company Bio


Medicenna Therapeutics Corp. operates as an immuno-oncology company. The Company develops and commercializes therapeutics for the treatment of central nervous system and urological cancers. Medicenna Therapeutics offers its services in Canada.


MDNA Latest News Stream


Event/Time News Detail
Loading, please wait...

MDNA Latest Social Stream


Loading social stream, please wait...

View Full MDNA Social Stream

Latest MDNA News From Around the Web

Below are the latest news stories about Medicenna Therapeutics Corp that investors may wish to consider to help them evaluate MDNA as an investment opportunity.

MDNA: Encouraging Early Clinical Data from ABILITY Study…

David Bautz, PhD NASDAQ:MDNA READ THE FULL MDNA RESEARCH REPORT Business Update Encouraging Early Clinical Data for ABILITY Trial On December 22, 2021, Medicenna Therapeutics Corp. (NASDAQ:MDNA) announced encouraging early clinical data from the Phase 1/2 ABILITY Study (A Beta-only IL-2 ImmunoTherapY Study) of MDNA11 in patients with advanced solid tumors. Following the first two dose escalation

Yahoo | February 15, 2022

Medicenna to Participate in the 11th Annual SVB Leerink Global Healthcare Conference

TORONTO and HOUSTON, Feb. 10, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that Dr. Fahar Merchant, President, CEO and Chairman of the Board of Medicenna, will participate in a Fireside Chat at the SVB Leerink Global Healthcare Conference, which is scheduled to take place virtually from February 14 – February 18, 2022. Details are as follows: 11th Annual SVB Leerink Global

Yahoo | February 10, 2022

Medicenna Reports Third Quarter Fiscal 2022 Financial Results and Operational Highlights

-- Phase 1/2 ABILITY study of MDNA11 on track with first set of efficacy results from early dose escalation cohorts expected in mid-calendar 2022 -- Preliminary pharmacodynamic data show preferential stimulation of anti-cancer immune cells with MDNA11 treatment in the ABILITY study -- First clinical site in the US open for enrolment -- Management hosting conference call and webcast today at 8:30 am ET TORONTO and HOUSTON, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna

Yahoo | February 9, 2022

Medicenna to Announce Third Quarter Fiscal 2022 Financial Results and Operational Highlights on Wednesday, February 9, 2022

TORONTO and HOUSTON, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. ("Medicenna" or “the Company") (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced that it will host a conference call and live webcast on February 9, 2022 at 8:30 AM ET to report its third quarter fiscal 2022 financial results and operational highlights. To access the call, please dial (877) 407-9716 from the Canada and the United States or (201) 493-6779 internationally, followed

Yahoo | February 2, 2022

Medicenna Announces Formation of its Scientific Advisory Board

TORONTO and HOUSTON, Jan. 31, 2022 (GLOBE NEWSWIRE) -- Medicenna Therapeutics Corp. (“Medicenna” or the “Company”) (NASDAQ: MDNA TSX: MDNA), a clinical stage immuno-oncology company, today announced the formation of its Scientific Advisory Board (SAB) comprised of thought leaders in cancer immunotherapy, immuno-engineering and immune monitoring. Chaired by Sergio Quezada, Ph.D., the SAB will work cohesively with management to explore the full potential of Medicenna’s Superkine platform. “I’m del

Yahoo | January 31, 2022

Read More 'MDNA' Stories Here

MDNA Price Returns

1-mo -8.18%
3-mo -32.67%
6-mo -46.28%
1-year -74.04%
3-year 59.06%
5-year N/A
YTD -38.04%
2021 -65.17%
2020 80.00%
2019 401.74%
2018 -67.63%
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.4281 seconds.